InSphero 3D InSight™ Microtissues Win "Best Technology" Award at ELRIG Research and Innovation Meeting
Schlieren, Switzerland - March 31, 2017 #ELRIGRI17
InSphero was announced on Thursday as winner of the ELRIG Research & Innovation "Best Technology" Award, recognizing an innovative portfolio of advanced 3D InSight™ Microtissues for drug safety and efficacy testing. The honor was awarded based on voting by attendees at the annual meeting, held this week at Homerton College in Cambridge, UK.
Amongst the topics of the 2017 scientific program were sessions on the scale-up of physiologically relevant 3D models, as well as innovative technologies for immuno-oncology and immunotherapy. InSphero's patent pending 3D Select™ Process enables industry-scale production of liver, pancreatic islet, and tumor microtissues that more accurately reflect in vivo tissue. InSphero's more physiologically relevant liver microtissues provide a more sensitive and highly specific in vitro model for predicting drug-induced liver injury, while islet and tumor microtissues are advanced models for diabetes and oncology drug discovery. InSphero will present its latest advances in the application of complex 3D tumor/stromal/immune co-culture microtissues for immuno-oncology drug development at next week's American Association of Cancer Research (AACR) Meeting in Washington, DC.
Dr. Adrian Rea, who with Dr. Andrea Lindemann accepted the award on behalf of InSphero, stated "We're hononored that our technology was recognized by the attendees at this year's ELRIG Research & Innovation Meeting. We enjoyed the opportunity to discuss the scientific benefits our microtissues have to offer with the attendees, and in turn learn from them about emerging trends in these exciting fields during the scientific sessions"
Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
Dr. Jan Lichtenberg
Chief Executive Officer, Co-founder
Phone +41 44 5150490
InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of organotypic 3D cell culture models. The company’s patented technologies include the 3D Select™ Process (pending) and scaffold-free 3D cell culture plates that enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, and tumors. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictive power at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.
Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with several national and international awards.
InSphero 3D InSight™ Human Liver Microtissues provide greater confidence to pharmaceutical drug discovery and development groups in their efforts to predict drug-induced liver injury in vitro prior to testing in animals or patients.